Is compounded tirzepatide legal in 2026?
Legal and FDA-approved are not the same thing. Here's where compounded tirzepatide stands in 2026 — and why the picture can shift.
Legal vs FDA-approved: two different questions
The most common confusion about compounded tirzepatide is treating "legal" and "FDA-approved" as the same thing. They are not. FDA approval refers to a specific finished drug product that the agency has reviewed and authorized — for tirzepatide, that's brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), both made by Eli Lilly. Compounding is a separate, long-standing pathway: licensed pharmacies preparing a medication for an individual patient under a valid prescription. Compounded tirzepatide is not FDA-approved as a finished product, yet compounding itself operates within a defined legal framework. See is compounded tirzepatide FDA-approved?
The framework compounding operates under
Federal law recognizes two compounding pathways. 503A pharmacies compound for individually identified patients pursuant to a prescription. 503B outsourcing facilities register with the FDA and meet stricter manufacturing standards, allowing larger-batch compounding. Both are subject to FDA oversight and to the rules of the states in which they're licensed. A provider using appropriately licensed pharmacies, a valid prescriber relationship, and a legitimate prescription is operating within that framework. See 503A vs 503B compounding.
Why the situation can change
Compounding rules interact with drug-shortage status. When a brand drug is in shortage, compounding of that molecule is generally more permissible; when the FDA declares a shortage resolved, the conditions around compounding that drug can tighten. The FDA has indicated the tirzepatide injection shortage was resolved, and the compounded GLP-1 space remains under active regulatory attention. That means the rules in effect today may not be the rules in effect later, and enforcement can evolve. This is not legal advice — it's a description of a moving landscape.
State-level differences
Telehealth prescribing and pharmacy licensure are also governed by state law, so availability and specifics differ by state. A provider must be able to connect you with a clinician licensed in your state and a pharmacy permitted to ship there. See our cost and availability by state pages, and confirm current details directly with any provider, since this content is educational and not a substitute for legal or medical advice.
What to verify before choosing
- That the dispensing pharmacy is a licensed 503A or 503B facility
- That a clinician licensed in your state issues the prescription
- Current FDA shortage status for tirzepatide and how the provider addresses it
- Whether the provider ships to and is permitted to operate in your state
- That you have a genuine clinical evaluation, not a rubber-stamp
Common questions
Is compounded tirzepatide legal in 2026?
Compounded medications are permitted under federal law when prepared by appropriately licensed 503A or 503B pharmacies for a valid prescription, subject to FDA and state rules. It is not the same as FDA approval, and the regulatory environment can change.
Is legal the same as FDA-approved?
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro and Zepbound are FDA-approved. Compounding is a separate legal pathway under FDA and state oversight.
Could the rules around compounded tirzepatide change?
Yes. Compounding permissibility is tied to drug-shortage status and enforcement, both of which can change. The FDA has indicated the tirzepatide shortage was resolved, and the area remains under scrutiny.